Focal liver lesion detection and characterization with GD-EOB-DTPA

Clinical Radiology

Volumn 66, Issue 7, 2011, Pages 673-684

  Purysko, A S ^a   Remer, E M ^a   Veniero, J C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECHOVIST; GADOLINIUM PENTETATE; GADOXETIC ACID; SODIUM CHLORIDE;

ASTHENIA; CHILL; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; DIAGNOSTIC VALUE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TOLERANCE; DRUG TRANSPORT; DRUG UPTAKE; FIRST PASS EFFECT; HEADACHE; HEPATOBILIARY SYSTEM; HUMAN; IMAGE ANALYSIS; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; KIDNEY FUNCTION; LIVER ADENOMA; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER EXAMINATION; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMANGIOMA; LIVER METASTASIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; SIDE EFFECT; SIGNAL DETECTION; TASTE DISORDER; TREMOR; VASODILATATION; VOMITING;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79957669526     PISSN: 00099260     EISSN: 1365229X     Source Type: Journal    
DOI: 10.1016/j.crad.2011.01.014     Document Type: Review

References (30)

1. Semelka RC, Shoenut P, Kroeker MA, et al. Focal liver disease: comparison of dynamic contrast enhanced CT and T2-weighted fat-suppressed, FLASH and dynamic gadolinium-enhanced MR imaging at 1.5 T. Radiology 1992;184:687-94.
2. Semelka RC, Martin DR, Balci C, et al. Focal liver lesions: comparison of dual phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging 2001;13:397-401. (Pubitemid 32173407)
3. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005;237:89-98. (Pubitemid 41346150)
4. Raman SS, Leary C, Bluemke DA, et al. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr 2010;34:163-72.
5. Zech CJ, Herrmann KA, Reiser MF, et al. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007;6:43-52.
6. Seale MK, Catalano OA, Saini S, et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. RadioGraphics 2009;29:1725-48.
7. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183:59-64.
8. Hamm B, Taks T, Muuhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetis, and MR imaging. Radiology 1995;195:785-92.
9. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison ofMR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67. (Pubitemid 26197732)
10. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991;22:233-7.
11. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific Gadoxetic Acid Disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006;30:345-54. (Pubitemid 43922248)
12. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715-24. (Pubitemid 41546838)
13. nd International Forum for Liver MRI. Eur Radiol 2009;19(Suppl 5):S975-89.
14. Tschirch FT, Struwe A, Petrowsky H, et al. Contrast-enhanced MR cholangiography with Gd-EOBDTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 2008;18:1577-86.
15. Quillin SP, Atilla S, Brown JJ, et al. Characterization of focal hepatic masses by dynamic contrast-enhanced MR imaging: findings in 311 lesions. Magn Reson Imaging 1997;3:275-85. (Pubitemid 27274252)
16. Doo KW, Lee CH, Choi JW, et al. "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009;193:W490-6.
17. Huurman VAL, Schaapherder AFM. Management of ruptured hepatocellular adenoma. Dig Surg 2010;27:56-60.
18. Marin D, Brancatelli G, Federle MP, et al. Focal nodular hyperplasia: typical and atypical MRI findings with emphasis on the use of contrast media. Clin Radiol 2008;63:577-85.
19. Zech CJ, Grazioli L, Breuer J, et al. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 2008;43:504-11.
20. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515-24.
21. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg 2010;27:39-45.
22. Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis: an entity distinct from liver adenoma? Gastroenterology 1985;89:1132-8.
23. Giovanoli O, Heim M, Terracciano L, et al. MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol 2008;190:W290-3.
24. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
25. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 2009;193:1053-60.
26. de Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002;14:159-65. (Pubitemid 34163995)
27. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (<2 cm in diameter) from arterial enhancing pseudolesions. Invest Radiol 2010;45:96-103.
28. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192:1675-81.
29. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255:459-66.
30. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18:457-67. (Pubitemid 351248177)